MD3774897T2 - Metode și sisteme de selectare și tratare a pacienților cu boli inflamatorii - Google Patents
Metode și sisteme de selectare și tratare a pacienților cu boli inflamatoriiInfo
- Publication number
- MD3774897T2 MD3774897T2 MDE20210158T MDE20210158T MD3774897T2 MD 3774897 T2 MD3774897 T2 MD 3774897T2 MD E20210158 T MDE20210158 T MD E20210158T MD E20210158 T MDE20210158 T MD E20210158T MD 3774897 T2 MD3774897 T2 MD 3774897T2
- Authority
- MD
- Moldova
- Prior art keywords
- cd30l
- ligand
- inhibitor
- treatment
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 102000004634 CD30 Ligand Human genes 0.000 abstract 9
- 108010017987 CD30 Ligand Proteins 0.000 abstract 9
- 239000003112 inhibitor Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 abstract 1
- 108010044023 Ki-1 Antigen Proteins 0.000 abstract 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 abstract 1
- 230000008512 biological response Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000010187 selection method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Inenţia descrie metode şi un sistem pentru identificarea subiecţilor adecvaţi pentru tratarea unei boli inflamatorii, o boală fibrostenică şi o boală fibrotică prin inhibarea sau reducerea activităţii sau expresiei ligandului CD30 (CD30L) la un subiect.În unele cazuri, inhibitorul CD30L inhibă, atenuează sau afectează într-un alt mod un răspuns biologic asociat cu interacţiunea CD30L cu antigenul său înrudit, CD30. Astfel, în unele cazuri, tratamentul cu un inhibitor CD30L este util pentru tratarea afecţiunilor cu care este asociată expresia sau activitatea ligandului CD30 sau CD30.Metodele şi sistemele de selecţie identifică subiecţii adecvaţi pentru tratament pe baza prezenţei unui genotip care indică o boală sau afecţiune la subiect pentru care un inhibitor al CD30L este un tratament adecvat.Deasemenea sunt prezentate compoziţii utilizate pentru detectarea genotipurilor descrise aici şi metodele de utilizare a acestora. Administrarea la subiect a unei cantităţi eficiente de inhibitor al ligandului CD30 pentru a inhiba sau reduce activitatea sau expresia ligandului CD30 la subiect.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664720P | 2018-04-30 | 2018-04-30 | |
| US201862681557P | 2018-06-06 | 2018-06-06 | |
| US201862784179P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/029402 WO2019212899A1 (en) | 2018-04-30 | 2019-04-26 | Methods and systems for selection and treatment of patients with inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3774897T2 true MD3774897T2 (ro) | 2024-02-29 |
Family
ID=68386125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20210158T MD3774897T2 (ro) | 2018-04-30 | 2019-04-26 | Metode și sisteme de selectare și tratare a pacienților cu boli inflamatorii |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20210238684A1 (ro) |
| EP (2) | EP3774897B1 (ro) |
| JP (2) | JP2021532060A (ro) |
| KR (1) | KR20210013062A (ro) |
| CN (1) | CN112368301A (ro) |
| AU (1) | AU2019261933A1 (ro) |
| CA (1) | CA3098720A1 (ro) |
| DK (1) | DK3774897T5 (ro) |
| ES (1) | ES2962715T3 (ro) |
| FI (1) | FI3774897T3 (ro) |
| HR (1) | HRP20231367T1 (ro) |
| HU (1) | HUE063908T2 (ro) |
| LT (1) | LT3774897T (ro) |
| MA (1) | MA52251A (ro) |
| MD (1) | MD3774897T2 (ro) |
| PL (1) | PL3774897T3 (ro) |
| PT (1) | PT3774897T (ro) |
| RS (1) | RS64747B1 (ro) |
| SI (1) | SI3774897T1 (ro) |
| TW (1) | TW202003573A (ro) |
| WO (1) | WO2019212899A1 (ro) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7559257B2 (ja) * | 2021-02-17 | 2024-10-01 | プロメテウス バイオサイエンシーズ，インク． | 抗ｃｄ３０ｌ抗体およびその使用 |
| WO2024026395A1 (en) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
| WO2024026386A1 (en) * | 2022-07-27 | 2024-02-01 | Cephalon Llc | Anti-tl1a antibody formulations |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| JPH0778017B2 (ja) | 1985-12-28 | 1995-08-23 | 住友製薬株式会社 | パルス的かつ持続放出性製剤 |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| US20060194265A1 (en) * | 2001-10-23 | 2006-08-31 | Morris David W | Novel therapeutic targets in cancer |
| US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2010127906A1 (en) * | 2009-03-27 | 2010-11-11 | Merck Serono S.A. | Genetic severity markers in multiple sclerosis |
| WO2011020906A2 (en) * | 2009-08-21 | 2011-02-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT |
| AU2013251541B2 (en) * | 2012-04-27 | 2018-01-25 | Amgen Inc. | Human CD30 ligand antigen binding proteins |
| WO2013181694A1 (en) * | 2012-06-04 | 2013-12-12 | Gaurav Agrawal | Compositions and methods for treating crohn's disease and related conditions and infections |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
-
2019
- 2019-04-26 EP EP19796203.8A patent/EP3774897B1/en active Active
- 2019-04-26 EP EP23192639.5A patent/EP4296285A3/en active Pending
- 2019-04-26 US US17/051,731 patent/US20210238684A1/en active Pending
- 2019-04-26 AU AU2019261933A patent/AU2019261933A1/en active Pending
- 2019-04-26 RS RS20231000A patent/RS64747B1/sr unknown
- 2019-04-26 CA CA3098720A patent/CA3098720A1/en active Pending
- 2019-04-26 DK DK19796203.8T patent/DK3774897T5/da active
- 2019-04-26 FI FIEP19796203.8T patent/FI3774897T3/fi active
- 2019-04-26 MD MDE20210158T patent/MD3774897T2/ro unknown
- 2019-04-26 MA MA052251A patent/MA52251A/fr unknown
- 2019-04-26 JP JP2020560463A patent/JP2021532060A/ja active Pending
- 2019-04-26 SI SI201930656T patent/SI3774897T1/sl unknown
- 2019-04-26 WO PCT/US2019/029402 patent/WO2019212899A1/en active Application Filing
- 2019-04-26 LT LTEPPCT/US2019/029402T patent/LT3774897T/lt unknown
- 2019-04-26 PT PT197962038T patent/PT3774897T/pt unknown
- 2019-04-26 KR KR1020207033851A patent/KR20210013062A/ko not_active Application Discontinuation
- 2019-04-26 HR HRP20231367TT patent/HRP20231367T1/hr unknown
- 2019-04-26 HU HUE19796203A patent/HUE063908T2/hu unknown
- 2019-04-26 CN CN201980044299.1A patent/CN112368301A/zh active Pending
- 2019-04-26 ES ES19796203T patent/ES2962715T3/es active Active
- 2019-04-26 PL PL19796203.8T patent/PL3774897T3/pl unknown
- 2019-04-30 TW TW108115107A patent/TW202003573A/zh unknown
-
2024
- 2024-06-03 JP JP2024090213A patent/JP2024133462A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3774897T5 (da) | 2024-08-19 |
| ES2962715T3 (es) | 2024-03-20 |
| PT3774897T (pt) | 2023-11-10 |
| EP3774897B1 (en) | 2023-09-27 |
| JP2024133462A (ja) | 2024-10-02 |
| LT3774897T (lt) | 2023-11-10 |
| EP4296285A3 (en) | 2024-02-28 |
| MA52251A (fr) | 2021-02-17 |
| TW202003573A (zh) | 2020-01-16 |
| AU2019261933A1 (en) | 2020-12-03 |
| EP3774897A4 (en) | 2022-02-16 |
| WO2019212899A1 (en) | 2019-11-07 |
| RS64747B1 (sr) | 2023-11-30 |
| SI3774897T1 (sl) | 2024-01-31 |
| KR20210013062A (ko) | 2021-02-03 |
| EP4296285A2 (en) | 2023-12-27 |
| HRP20231367T1 (hr) | 2024-02-16 |
| US20210238684A1 (en) | 2021-08-05 |
| EP3774897A1 (en) | 2021-02-17 |
| CA3098720A1 (en) | 2019-11-07 |
| JP2021532060A (ja) | 2021-11-25 |
| FI3774897T3 (fi) | 2023-11-03 |
| HUE063908T2 (hu) | 2024-02-28 |
| PL3774897T3 (pl) | 2024-01-29 |
| DK3774897T3 (da) | 2023-11-06 |
| CN112368301A (zh) | 2021-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3774897T2 (ro) | Metode și sisteme de selectare și tratare a pacienților cu boli inflamatorii | |
| Tu et al. | Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease | |
| Mahfoud et al. | Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension | |
| BRPI0512500A (pt) | tratamento ou condições envolvendo desmielinação | |
| ATE470151T1 (de) | Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern | |
| BR112013023724A2 (pt) | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento | |
| DE60122673D1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| Armelin et al. | The nonpharmacological sequence method provides a reliable evaluation of baroreflex sensitivity in fish | |
| ATE546547T1 (de) | Diagnose der chronischen abstossung | |
| Stevenson et al. | A “gap effect” on stop signal reaction times in a human saccadic countermanding task | |
| DE602004027613D1 (de) | Therapeutische, prophylaktische und diagnostische wirkstoffe | |
| WO2018176066A3 (en) | Cord blood therapy to treat chronic disease caused by l-form bacteria | |
| Goode et al. | Relapse of extinguished fear after exposure to a dangerous context is mitigated by testing in a safe context | |
| Tank et al. | Sympathetic nerve traffic and circulating norepinephrine levels in RGS2-deficient mice | |
| Busin | Treatment of sheep scab in the UK: preventing the spread of resistant mites | |
| Lombardo | Vancomycin-resistant enterococcal (VRE) titers diminish among patients with recurrent Clostridium difficile infection after administration of SER-109, a novel microbiome agent | |
| Lim et al. | PWE-138 Repetitive belching is predictive of supragastric belching diagnosis | |
| Curry et al. | PIN9 CLINICAL PRACTICE EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) FOR TREATMENT OF HEPATITIS B IN THE US | |
| Kopczynska et al. | 1565: RED FLAG SEPSIS TOOL OR SOFA FOR SEPSIS SCREENING ON THE WARD: SEARCHING FOR THE BEST SOLUTION | |
| Sharma et al. | 568: ACUTE NEUROLOGICAL INJURY MONITORING WITH EQUANOX (ANIME) STUDY | |
| Jin | Unmasking ethnic inequities in rising blood pressure: insights from the HELIUS study | |
| McKelvie | Compared with low-dose losartan, high-dose losartan decreases risk of death or hospital admission for heart failure in people with heart failure who are intolerant to ACE inhibitors | |
| Meng et al. | 1042: Effects of statin and fibrate on outcomes of sepsis | |
| Uchida | Leukocytoclastic vasculitis: case report | |
| TJ | Microalbuminuria screening good for diabetic, hypertensive patients |